CCNA1 TCRs for AML and solid tumors
High-affinity HLA-A2 restricted TCRs for the treatment of AML and several solid tumors.
- Stage: Preclinical in vivo
- Type: Cell Therapy
- Categories: Immuno Oncology
Technology Overview
Cancer-testis antigen cyclin A1 (CCNA1) is an alternative A-type cyclin and is thought to promote cell proliferation (specifically at the G1/S transition) and survival, has been shown to be leukemogenic in mice. It is overexpressed in ≥50% Acute Myeloid Leukemia (AML) and ovarian cancer. This overexpression is associated with poor prognosis and shorter survival rates in AML patients. Dr. Phil Greenberg’s lab at Fred Hutchinson Cancer Center have identified high affinity HLA-A2 restricted TCRs that can selectively recognize and attack CCNA1-positive cancer cells. These TCRs demonstrate potent cytotoxicity against CCNA1-expressing cells. Preclinical studies validate their efficacy, with progress made towards clinical trials.
Applications
- AML, ovarian, cervical, head and neck, bladder and other epithelial cancers
Advantages
- High-affinity TCRs selected from high-avidity clones
- Kills leukemia cell lines and primary AML
Patent Information
- PCT Application Filed
Investigator Overview
- Philip Greenberg, MD, Professor & Head, Program in Immunology, Clinical Research Division, Fred Hutch;
The Rona Jaffe Foundation Endowed Chair, Fred Hutch